Patents Assigned to Celgene Corporation
  • Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
    Patent number: 11014897
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to (Z)-5-((Z)-3-chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Lianfeng Huang, Daozhong Zou
  • Thiazolidinone and oxazolidinone compounds and formulations
    Patent number: 11014940
    Abstract: Provided herein are thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV). Also provided herein are uses of these thiazolidinone and oxazolidinone compounds such as Compound 1, 1A, 1B, 1C, 1D, 1E, 1F, and compounds of Formulas (I), (II), (III), and (IV), pharmaceutical compositions and formulations in the treatment of various diseases, including but not limited to diseases or disorders associated with an activated immune system (e.g., multiple sclerosis and psoriasis).
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 25, 2021
    Assignee: CELGENE CORPORATION
    Inventors: John Fitzgerald Traverse, Sanjeevani Ghone, Fu-An Kang, Francisco Velazquez
  • USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210128619
    Abstract: Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicants: CELGENE CORPORATION, JUNO THERAPEUTICS, INC., BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Timothy CAMPBELL, Ronald HAUSE, Kristen HEGE, Yue JIANG, Shari KAISER, Ethan THOMPSON, Jaymes FULLER, Nathan MARTIN, Rong LIU, Justine DELL'ARINGA
  • Methods for determining drug efficacy for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancers
    Patent number: 10996215
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 4, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle Macbeth
  • METHODS FOR TREATING A HEMATOLOGICAL CANCER AND THE USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE
    Publication number: 20210116454
    Abstract: A method of identifying a subject having a hematological cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the hematological cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
    Type: Application
    Filed: October 20, 2020
    Publication date: April 22, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Maria Soraya Carrancio ANTON, Celia Fontanillo FONTANILLO, Shailaja KASIBHATLA, Antonia LOPEZ-GIRONA, Gang LU, Kai WANG
  • 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
    Patent number: 10980812
    Abstract: Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE). Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.
    Type: Grant
    Filed: February 25, 2020
    Date of Patent: April 20, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Peter H. Schafer, Lei Wu, Ying Ye
  • Methods of improving vector transduction efficiency into T lymphocytes
    Patent number: 10982189
    Abstract: Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: April 20, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Bitao Liang, Wei Liu
  • Combination therapy for treatment of hematological cancers and solid tumors
    Patent number: 10973822
    Abstract: Provided herein are methods for treating, preventing, and/or managing hematological cancers and solid tumors using combination therapy of 3-(5-amino-2-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione and checkpoint inhibitors.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: April 13, 2021
    Assignee: Celgene Corporation
    Inventors: Anita Gandhi, Hsiling Chiu, Michael Pourdehnad
  • METHODS FOR MEASURING SMALL MOLECULE AFFINITY TO CEREBLON
    Publication number: 20210102938
    Abstract: A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.
    Type: Application
    Filed: September 18, 2020
    Publication date: April 8, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Philip Paul CHAMBERLAIN, Mary MATYSKIELA, Godrej KHAMBATTA
  • METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR TO RESPONSIVENESS TO DRUGS
    Publication number: 20210102257
    Abstract: In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
    Type: Application
    Filed: May 18, 2020
    Publication date: April 8, 2021
    Applicant: Celgene Corporation
    Inventors: Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
  • Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
    Patent number: 10969381
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: April 6, 2021
    Assignee: Celgene Corporation
    Inventors: Joshua Hansen, Courtney G. Havens, Antonia Lopez-Girona, Gang Lu, Lilly L. Wong
  • Modified T lymphocytes comprising a BAFF antibody-inducible caspase and methods of apoptosis
    Patent number: 10967005
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: April 6, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • COMBINATION THERAPY USING ADOPTIVE CELL THERAPY AND CHECKPOINT INHIBITOR
    Publication number: 20210069246
    Abstract: Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of a checkpoint inhibitor, such as an anti-PD-L1 antibody or antigen-binding fragment thereof for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.
    Type: Application
    Filed: January 31, 2019
    Publication date: March 11, 2021
    Applicant: Celgene Corporation
    Inventors: Stanley R. FRANKEL, Jens HASSKARL, Oliver MANZKE
  • Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
    Patent number: 10919873
    Abstract: Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate. Pharmaceutical compositions comprising the crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate are also disclosed.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: February 16, 2021
    Assignee: Celgene Corporation
    Inventor: Jerry Lee Atwood
  • Treatment of immune-related and inflammatory diseases
    Patent number: 10919883
    Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: February 16, 2021
    Assignee: Celgene Corporation
    Inventors: Peter H. Schafer, Rajesh Chopra, Anita Gandhi
  • Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
    Patent number: 10898488
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: January 26, 2021
    Assignee: Celgene Corporation
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • METHODS OF TREATING HEMATOLOGICAL DISORDERS, SOLID TUMORS, OR INFECTIOUS DISEASES USING NATURAL KILLER CELLS
    Publication number: 20210008109
    Abstract: Provided herein are methods of treating a hematological disorder, a solid tumor, or an infectious disease in a subject in need thereof using natural killer cells in combination with a second agent, or using natural killer cells with genetic modifications for target specificity and/or homing specificity.
    Type: Application
    Filed: February 18, 2020
    Publication date: January 14, 2021
    Applicant: CELGENE CORPORATION
    Inventors: Lin KANG, Xiaokui ZHANG, Jeffrey HARRIS, Vladimir JANKOVIC
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20210000813
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: April 17, 2020
    Publication date: January 7, 2021
    Applicant: Celgene Corporation
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • COMPOSITIONS AND METHODS FOR INDUCING CONFORMATIONAL CHANGES IN CEREBLON AND OTHER E3 UBIQUITIN LIGASES
    Publication number: 20210003557
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 7, 2021
    Applicant: Celgene Corporation
    Inventors: Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
  • METHODS OF EXPANDING T CELLS
    Publication number: 20200407681
    Abstract: Provided herein are methods in the field of cell culture, specifically of culture and expansion of immune cells, e.g., T lymphocytes.
    Type: Application
    Filed: April 15, 2020
    Publication date: December 31, 2020
    Applicant: CELGENE CORPORATION
    Inventors: Stewart Abbot, Willard Foss, Thomas Daniel